Hemostemix (CVE:HEM) Stock Price Up 27.8% – Time to Buy?

Shares of Hemostemix Inc. (CVE:HEMGet Free Report) traded up 27.8% on Saturday . The company traded as high as C$0.12 and last traded at C$0.12. 335,071 shares traded hands during trading, a decline of 31% from the average session volume of 486,759 shares. The stock had previously closed at C$0.09.

Hemostemix Trading Up 27.8%

The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The business has a 50-day moving average of C$0.10 and a two-hundred day moving average of C$0.14. The firm has a market capitalization of C$16.76 million, a price-to-earnings ratio of -3.35 and a beta of 0.20.

Insider Buying and Selling at Hemostemix

In related news, Director Peter Alan Lacey acquired 200,000 shares of the firm’s stock in a transaction on Thursday, March 6th. The shares were bought at an average cost of C$0.15 per share, with a total value of C$30,000.00. Company insiders own 10.43% of the company’s stock.

About Hemostemix

(Get Free Report)

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.

Read More

Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.